At the time of writing, MaxCyte Inc [MXCT] stock is trading at $3.54, up 3.21%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling.
From an analyst’s perspective:
MaxCyte Inc [NASDAQ: MXCT] stock has seen the most recent analyst activity on November 29, 2023, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $7. On August 24, 2021, William Blair initiated with a Outperform rating. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $36 on August 24, 2021. Stifel initiated its recommendation with a Buy and recommended $18 as its price target on August 24, 2021. Stephens started tracking with a Overweight rating for this stock on August 24, 2021, and assigned it a price target of $19. In a note dated August 24, 2021, Cowen initiated an Outperform rating.
For the past year, the stock price of MaxCyte Inc fluctuated between $3.16 and $5.26. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. MaxCyte Inc [NASDAQ: MXCT] shares were valued at $3.54 at the most recent close of the market. An investor can expect a potential return of 125.99% based on the average MXCT price forecast.
Analyzing the MXCT fundamentals
According to MaxCyte Inc [NASDAQ:MXCT], the company’s sales were 45.60M for trailing twelve months, which represents an 1.99% jump. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -1.02%, Pretax Profit Margin comes in at -0.78%, and Net Profit Margin reading is -0.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.16 and Total Capital is -0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.46 points at the first support level, and at 3.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.60, and for the 2nd resistance point, it is at 3.65.
Ratios To Look Out For
It is important to note that MaxCyte Inc [NASDAQ:MXCT] has a current ratio of 9.81. In addition, the Quick Ratio stands at 9.22 and the Cash Ratio stands at 2.1. Considering the valuation of this stock, the price to sales ratio is 8.19, the price to book ratio is 1.75.
Transactions by insiders
Recent insider trading involved Johnston John Joseph, Director, that happened on Jan 27 ’25 when 3000.0 shares were sold. GENERAL COUNSEL, Sandoval David I. completed a deal on Jan 13 ’25 to sell 4466.0 shares. Meanwhile, Director Johnston John Joseph sold 3000.0 shares on Dec 26 ’24.
